Trust Company of Vermont’s Oncolytics Biotech ONCY Stock Holding History

Trust Company of Vermont’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,000	Closed	-$6K	–	946
2022 Q3	$6K	Hold	5,000	–	–	﹤0.01%	814
2022 Q2	$5K	Buy	+5,000	New	+$6.08K	﹤0.01%	787
2022 Q1	–	Sell	-5,000	Closed	-$7K	–	618
2021 Q4	$7K	Buy	+5,000	New	+$9.24K	﹤0.01%	701
2021 Q3	–	Sell	-5,000	Closed	-$14K	–	593
2021 Q2	$14K	Hold	5,000	–	–	﹤0.01%	608
2021 Q1	$19K	Hold	5,000	–	–	﹤0.01%	561
2020 Q4	$12K	Hold	5,000	–	–	﹤0.01%	607
2020 Q3	$8K	Hold	5,000	–	–	﹤0.01%	631
2020 Q2	$9K	Hold	5,000	–	–	﹤0.01%	638
2020 Q1	$7K	Hold	5,000	–	–	﹤0.01%	712
2019 Q4	$24K	Buy	+5,000	New	+$5.64K	﹤0.01%	582

Other funds holding ONCY

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Trust Company of Vermont's ONCY Position: Q4 2022 in Review

Trust Company of Vermont sold out of Oncolytics Biotech (ONCY) in Q4 2022, closing a stake of 5,000 shares — an estimated $6K sold.

Trust Company of Vermont first reported a position in ONCY in Q4 2019 and held it in 10 quarters. The position peaked at $24K in Q4 2019. 35 funds tracked by Wall St. Rank hold ONCY as of Q4 2022.

Trust Company of Vermont reported no remaining Oncolytics Biotech position as of Q4 2022 after selling out during the quarter.
Trust Company of Vermont sold 5,000 Oncolytics Biotech shares in Q4 2022, an estimated $6K.
Trust Company of Vermont first reported a position in Oncolytics Biotech in Q4 2019 and held it in 10 quarters.
Trust Company of Vermont's Oncolytics Biotech position peaked at $24K in Q4 2019.
35 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2022.

Based on Trust Company of Vermont's 13F filing for Q4 2022, filed 9 Feb 2023.